These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
132 related articles for article (PubMed ID: 3181045)
41. [Hypolipemic effects of a new tetralin derivative: compound 13473-Su (Ciba)]. Ciobanu V; Zălaru MC; Ciocan A; Mihăilescu S Stud Cercet Med Interna; 1971; 12(1):67-80. PubMed ID: 5565781 [No Abstract] [Full Text] [Related]
42. [Serum cholesterol in endogenous hyperlipidemia (type IV)]. Wille LE Tidsskr Nor Laegeforen; 1972 Nov; 92(31):2089-92. PubMed ID: 4656549 [No Abstract] [Full Text] [Related]
43. Twenty-year trends in serum cholesterol, hypercholesterolemia, and cholesterol medication use: the Minnesota Heart Survey, 1980-1982 to 2000-2002. Arnett DK; Jacobs DR; Luepker RV; Blackburn H; Armstrong C; Claas SA Circulation; 2005 Dec; 112(25):3884-91. PubMed ID: 16344385 [TBL] [Abstract][Full Text] [Related]
44. Serum lipids and lipoproteins in first degree relatives of young survivors of myocardial infarction. Aro A Acta Med Scand Suppl; 1973; 553():1-103. PubMed ID: 4550038 [No Abstract] [Full Text] [Related]
45. [Current trends in the therapy of arteriosclerotic disease]. Toscano S G Clin Med; 1974 Jan; 55(1):27-39. PubMed ID: 4369524 [No Abstract] [Full Text] [Related]
46. Treatment of hypercholesterolaemia with colestipol: a bile sequestrating agent. Nye ER; Jackson D; Hunter JD N Z Med J; 1972 Jul; 76(482):12-6. PubMed ID: 4344110 [No Abstract] [Full Text] [Related]
47. Effects of fluvastatin, a new inhibitor of HMG-CoA reductase, and niceritrol on serum lipids, lipoproteins and cholesterol ester transfer activity in primary hypercholesterolemic patients. Sasaki J; Yamamoto K; Kobori S; Setoguchi Y; Sato Y; Matsunaga A; Shichiri M; Sakai T; Kono S; Arakawa K Int J Clin Pharmacol Ther; 1995 Jul; 33(7):420-6. PubMed ID: 7582401 [TBL] [Abstract][Full Text] [Related]
48. Experience with crystalline niacin as the preferred drug for dyslipidemia in a specialty clinic. Rindone JP; Arriola OG Pharmacotherapy; 1997; 17(6):1296-9. PubMed ID: 9399614 [TBL] [Abstract][Full Text] [Related]
49. [Antilipemic drugs]. Schwandt P Med Monatsschr Pharm; 1980 Oct; 3(10):302-5. PubMed ID: 7007844 [No Abstract] [Full Text] [Related]
50. [AVERT study (Atorvastatin Versus Revascularization Treatment). Clinical advantage of aggressive lipid lowering]. Z Kardiol; 1999 Mar; 88(3 Suppl):1-4. PubMed ID: 10330699 [No Abstract] [Full Text] [Related]
51. No effect of activated charcoal on hyperlipidaemia. A double-blind prospective trial. Hoekstra JB; Erkelens DW Neth J Med; 1988 Dec; 33(5-6):209-16. PubMed ID: 3065658 [No Abstract] [Full Text] [Related]
52. [Medical recommendations and references about hypolipidemic drugs. ANDEM (National Agency for the Development of Medical Evaluation]. J Mal Vasc; 1997 Oct; 22(4):249-64. PubMed ID: 9411011 [No Abstract] [Full Text] [Related]
53. [Studies on the effect of d-thyroxine in patients with increased serum lipid level]. Steger H Wien Klin Wochenschr; 1968 Nov; 80(47):887-98. PubMed ID: 5717659 [No Abstract] [Full Text] [Related]
58. Effects of gemfibrozil on plasma lipoprotein-apolipoprotein distribution and platelet reactivity in patients with hypertriglyceridemia. Sirtori CR; Franceschini G; Gianfranceschi G; Sirtori M; Montanari G; Tremoli E; Maderna P; Colli S; Zoppi F J Lab Clin Med; 1987 Sep; 110(3):279-86. PubMed ID: 3475394 [TBL] [Abstract][Full Text] [Related]
59. [Therapeutic trial of a normolipemic agent: ethanolamine N-oxy-nicotinate]. Warembourg H; Ketelers JY; Ginestet A Lille Med; 1973 Dec; 18(10 Suppl 5):suppl 5:1331-5. PubMed ID: 4608970 [No Abstract] [Full Text] [Related]
60. Long term human studies on the lipid effects of oral calcium. Bierenbaum ML; Fleischman AI; Raichelson RI Lipids; 1972 Mar; 7(3):202-6. PubMed ID: 5021330 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]